Pharmaceutical Technology's In the Lab eNewsletter
Cambrex’s expanded quality control laboratory supports generic API development.
Cambrex Corporation announced the opening of a 120-sq.-m quality control (QC) laboratory at its site in Paullo, Milan, Italy, expanding the existing QC facilities to analyze and test generic API products during development and manufacturing.
The additional laboratory space, which is operational following authorization by the Agenzia Italiana Del Farmaco, features a new polarimeter and infrared spectrometer, along with electronic data capturing software for traceability in line with regulatory requirements.
“Our facility in Milan is the center of the Cambrex’s generic API business, and this investment is the latest in a number of steps we have taken at the site to increase its efficiency and flexibility as we look to grow the portfolio of products that we offer,” commented Aldo Magnini, managing director, Cambrex Milan, in an April 23, 2019 press statement. “In the last year the company has made strategic investments to expand its capabilities in research and development, manufacturing, and now QC capabilities, as we look to take advantage of the opportunities that are arising in the generic market.”
Cambrex manufactures more than 70 generic APIs, which are produced to cGMP standards at the Milan site; seven production departments are supported by a pilot plant, kilo scale plant, and development and analytical laboratories.
Source: Cambrex Corporation
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.